Roche's AXELIOS 1 enters next generation DNA sequencing. Can it or rivals unseat Illumina's long-standing market dominance?

With 10 cases in 2025, Guinea worm could be the second disease ever eradicated. Here is what makes disease eradication ...

New therapies in the clinic for bipolar disorder hope to meet unmet needs of efficacy and minimal side effects.

With a major restructuring currently underway, we take a look at Takeda's pipeline strategy – including three planned major ...

June 2026 saw drug development in oncology and neurology continue and biotech deals over small molecules and RNA therapies ...

Artificial intelligence (AI) may be transforming drug discovery, but one of the industry’s biggest problems remains unchanged: much of the biology used to develop new medicines still does not fully ...

Over the past year, a growing number of companies have relaunched under fresh brands, often accompanied by promises of a new chapter, renewed focus, or a transformed business strategy. On the surface, ...

For a long time, neurological drug development has largely focused on the cells that ultimately die or malfunction. Alzheimer’s researchers chased amyloid and tau. Parkinson’s drug development ...

A shift in the European pharma sector’s center of gravity might be underway as Spain continues to build on its reputation for innovative biotechnology and life science. Now ranked third in scientific ...

Atopic dermatitis is a chronic, relapsing inflammatory skin disorder characterized by eczematous lesions and intense itchiness, which can substantially impair an individual’s quality of life. Over the ...

U.K.-based biotech Allergy Therapeutics is focused on diagnosing and developing treatments for allergic disorders, including aluminium-free immunotherapies that have the potential to cure disease. The ...